ProKidney's Darin J. Weber converts 200K shares

A Class B share and its paired Common Unit may be exchanged for one Class A share, subject to agreement limitations.

Rhea-AI Filing Summary

ProKidney Corp. Chief Regulatory Officer Darin J. Weber converted 200,000 shares of Class B Common Stock and 200,000 Common Units into 200,000 shares of Class A Common Stock on October 28, 2026. The paired securities may be exchanged one-for-one, subject to limitations in the applicable agreements. The reported post-transaction positions were 202,283 Class B shares, 202,283 Common Units, and 200,000 Class A shares.

Insider Trade Summary

400,000 shares exercised/converted

Exercise 3 txns

Insider Weber Darin J.

Role Chief Regulatory Officer

Type	Security	Shares	Price	Value
Conversion	Class B Common Stock F1, F2	200,000	$0.00	$0.00
Conversion	Common Units in ProKidney Holdings, LLC F1, F3	200,000	$0.00	$0.00
Conversion	Class A Common Stock	200,000	$0.00	$0.00

Holdings After Transaction: Class B Common Stock — 202,283 contracts (Direct); Common Units in ProKidney Holdings, LLC — 202,283 contracts (Direct); Class A Common Stock — 200,000 shares (Direct)

Footnotes (3)

1. F1. The shares of Class B Common Stock and the Common Units in ProKidney Holdings LLC (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Amended and Restated Exchange Agreement, dated as of July 1, 2025, and the Second Amended and Restated Limited Liability Company Agreement of ProKidney Holdings, LLC, each share of Class B Common Stock, together with a paired Common Unit, may be exchanged for a share of Class A Common stock on a one-for-one basis.
2. F2. The shares of Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The shares of Class B Common Stock do not expire.
3. F3. The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

Key Figures

Class B Common Stock converted: 200,000 shares Common Units converted: 200,000 Common Units Class A Common Stock acquired: 200,000 shares +4 more

7 metrics

Class B Common Stock converted 200,000 shares October 28, 2026

Common Units converted 200,000 Common Units October 28, 2026

Class A Common Stock acquired 200,000 shares October 28, 2026

Conversion ratio 1 Class A share for each paired Class B share and Common Unit Exchange terms

Class B Common Stock following transaction 202,283 shares Reported after the October 28, 2026 transaction

Common Units following transaction 202,283 Common Units Reported after the October 28, 2026 transaction

Class A Common Stock following transaction 200,000 shares Reported after the October 28, 2026 transaction

Key Terms

paired securities, one-for-one basis, Amended and Restated Exchange Agreement, Common Unit

4 terms

paired securities technical

"The shares of Class B Common Stock and the Common Units ... are paired securities"

one-for-one basis technical

"exchanged for a share of Class A Common stock on a one-for-one basis"

Amended and Restated Exchange Agreement technical

"limitations set forth in the Amended and Restated Exchange Agreement"

Common Unit technical

"each share of Class B Common Stock, together with a paired Common Unit"

A common unit is a single piece of ownership in a company, fund, or trust—similar to an ordinary share but often used for pooled vehicles or listings where securities are packaged or governed differently. It matters to investors because each unit represents a claim on profits and, commonly, voting power; like holding a seat at a table, the number of units you own affects your share of returns and influence, and unit structures can also affect liquidity and tax treatment.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PROK shares did Darin J. Weber acquire in the conversion?

ProKidney Corp. Chief Regulatory Officer Darin J. Weber acquired 200,000 shares of Class A Common Stock on October 28, 2026, while converting 200,000 Class B shares and 200,000 paired Common Units. Each paired set may be exchanged for one Class A share, subject to the applicable agreement limitations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/30/2026 - 04:04 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weber Darin J.

(Last) (First) (Middle)

C/O PROKIDNEY CORP

2000 FRONTIS PLAZA BLVD, SUITE 250

(Street)

WINSTON-SALEM NORTH CAROLINA 27103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROKIDNEY CORP. [ PROK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/28/2026		C		200,000	A	$0	200,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Class B Common Stock(1)	$0	10/28/2026		C			200,000	(2)	(2)	Class A Common Stock	200,000	$0	202,283	D
Common Units in ProKidney Holdings, LLC(1)	$0	10/28/2026		C			200,000	(3)	(3)	Class A Common Stock	200,000	$0	202,283	D

Explanation of Responses:

1. The shares of Class B Common Stock and the Common Units in ProKidney Holdings LLC (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Amended and Restated Exchange Agreement, dated as of July 1, 2025, and the Second Amended and Restated Limited Liability Company Agreement of ProKidney Holdings, LLC, each share of Class B Common Stock, together with a paired Common Unit, may be exchanged for a share of Class A Common stock on a one-for-one basis.

2. The shares of Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The shares of Class B Common Stock do not expire.

3. The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

	/s/ Todd Girolamo, attorney in fact	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)